VOZRIA
LIVE

Serial Number

79306175

Owner

GLAXO GROUP LIMITED

Filing Date

Jan 8, 2021

Add to watchlist:

No watchlists yet
View on USPTO

VOZRIA Trademark

Serial Number: 79306175 • Registration: 6549771

VOZRIA is a trademark filed by GLAXO GROUP LIMITED on January 8, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

GLAXO GROUP LIMITED (5,077 trademarks)

980 Great West Road
Brentford, Middlesex TW89GS , GB

Entity Type: 03

Trademark Details

Filing Date

January 8, 2021

Registration Date

November 9, 2021

Published for Opposition

August 24, 2021

Goods & Services

Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders, namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), hpv, rsv, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders, namely, disorders of the endocrine system, namely, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders, namely, arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment, namely, nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders, namely, thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries, namely, connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders, namely, dermatitis, skin and skin structure infections, namely, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders, namely, hypogonadism, testosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders, namely, irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunction, namely, erectile dysfunction, male and female sexual dysfunction disorders, namely, arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders, namely, amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders, namely, polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases, namely, hepatitis, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 30, 2025 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 30, 2023 ADCH
NOTIFICATION PROCESSED BY IB
Mar 12, 2022 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Feb 23, 2022 FICS
FINAL DISPOSITION PROCESSED
Feb 22, 2022 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Dec 9, 2021 GPAR
REGISTERED-PRINCIPAL REGISTER
Nov 9, 2021 R.PR
PUBLISHED FOR OPPOSITION
Aug 24, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Aug 22, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 4, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 4, 2021 OP2R
NOTICE OF PUBLICATION
Aug 4, 2021 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 20, 2021 CNSA
ASSIGNED TO EXAMINER
Jul 19, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 19, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 12, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 11, 2021 REPR